Derek Hicks - 03 Jan 2022 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Business Officer
Signature: /s/ James Basta, Attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 03 Jan 2022
Transactions value $: $0
Form type: 4
Filing time: 05 Jan 2022, 15:15:28 UTC
Previous filing: 29 Dec 2021
Next filing: 06 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Award	$0	+19.1K		$0.00	19.1K	03 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock option (right to buy)	Award	$0	+25K		$0.00	25K	03 Jan 2022	Common Stock	25K	$118.99	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2	This option was granted on January 3, 2022 with respect to 25,000 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 25% vesting on December 20, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter.